BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12904080)

  • 1. Bispyridinium cyclophanes: novel templates for human choline kinase inhibitors.
    Conejo-García A; Campos JM; Sánchez-Martín RM; Gallo MA; Espinosa A
    J Med Chem; 2003 Aug; 46(17):3754-7. PubMed ID: 12904080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel 4-amino bis-pyridinium and bis-quinolinium derivatives as choline kinase inhibitors with antiproliferative activity against the human breast cancer SKBR-3 cell line.
    Gómez-Pérez V; McSorley T; See Too WC; Konrad M; Campos JM
    ChemMedChem; 2012 Apr; 7(4):663-9. PubMed ID: 22278967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of the linker in bispyridium compounds on the inhibition of human choline kinase.
    Conejo-García A; Báñez-Coronel M; Sánchez-Martín RM; Rodríguez-González A; Ramos A; Ramírez de Molina A; Espinosa A; Gallo MA; Campos JM; Lacal JC
    J Med Chem; 2004 Oct; 47(22):5433-40. PubMed ID: 15481981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LUMO energy of model compounds of bispyridinium compounds as an index for the inhibition of choline kinase.
    Campos J; del Carmen Núñez M; Rodríguez V; Entrena A; Hernández-Alcoceba R; Fernández F; Lacal JC; Gallo MA; Espinosa A
    Eur J Med Chem; 2001 Mar; 36(3):215-25. PubMed ID: 11337100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological activity of new bispyridinium salts of 4,4'-bispyridyl-5,5'-perfluoroalkyl-2,2'-bisoxazoles.
    Martín-Cantalejo Y; Sáez B; Monterde MI; Murillo MT; Braña MF
    Eur J Med Chem; 2011 Nov; 46(11):5662-7. PubMed ID: 21996467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choline kinase inhibitory effect and antiproliferative activity of new 1,1',1"-(benzene-1,3,5-triylmethylene)tris[4-[(disubstituted)amino]pyridinium] tribromides.
    Conejo-García A; Campos J; Sánchez RM; Rodríguez-González A; Lacal JC; Gallo MA; Espinosa A
    Eur J Med Chem; 2003 Jan; 38(1):109-16. PubMed ID: 12593921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1).
    Schiaffino-Ortega S; Baglioni E; Mariotto E; Bortolozzi R; Serrán-Aguilera L; Ríos-Marco P; Carrasco-Jimenez MP; Gallo MA; Hurtado-Guerrero R; Marco C; Basso G; Viola G; Entrena A; López-Cara LC
    Sci Rep; 2016 Mar; 6():23793. PubMed ID: 27029499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (Q)SAR studies to design new human choline kinase inhibitors as antiproliferative drugs.
    Campos JM; Sánchez-Martín RM; Conejo-García A; Entrena A; Gallo MA; Espinosa A
    Curr Med Chem; 2006; 13(11):1231-48. PubMed ID: 16712467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a new binding site on human choline kinase α1: design, synthesis, crystallographic studies, and biological evaluation of asymmetrical bispyridinium derivatives.
    Rubio-Ruiz B; Figuerola-Conchas A; Ramos-Torrecillas J; Capitán-Cañadas F; Ríos-Marco P; Carrasco MP; Gallo MÁ; Espinosa A; Marco C; Ruiz C; Entrena A; Hurtado-Guerrero R; Conejo-García A
    J Med Chem; 2014 Jan; 57(2):507-15. PubMed ID: 24387243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead optimization-hit expansion of new asymmetrical pyridinium/quinolinium compounds as choline kinase α1 inhibitors.
    Rubbini G; Buades-Martín AB; Kimatrai-Salvador M; Entrena A; Gallo-Mezo MÁ; Ríos-Marco P; Marco C; Mattiuzzo E; Bortolozzi R; Mariotto E; Greco FA; Macchiarulo A; Carrasco-Jiménez MP; Viola G; López-Cara LC
    Future Med Chem; 2018 Aug; 10(15):1769-1786. PubMed ID: 30043647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New more polar symmetrical bipyridinic compounds: new strategy for the inhibition of choline kinase α1.
    Castro-Navas FF; Schiaffino-Ortega S; Carrasco-Jimenez MP; Ríos-Marco P; Marco C; Espinosa A; Gallo MA; Mariotto E; Basso G; Viola G; Entrena-Guadix A; López-Cara LC
    Future Med Chem; 2015; 7(4):417-36. PubMed ID: 25875870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a model for the inhibition of choline kinase by a new type of inhibitor.
    Conejo-García A; Entrena A; Campos JM; Sánchez-Martín RM; Gallo MA; Espinosa A
    Eur J Med Chem; 2005 Mar; 40(3):315-9. PubMed ID: 15725501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New non-symmetrical choline kinase inhibitors.
    Schiaffino-Ortega S; López-Cara LC; Ríos-Marco P; Carrasco-Jimenez MP; Gallo MA; Espinosa A; Marco C; Entrena A
    Bioorg Med Chem; 2013 Nov; 21(22):7146-54. PubMed ID: 24080101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. QSAR-derived choline kinase inhibitors: how rational can antiproliferative drug design be?
    Campos J; Núñez MC; Conejo-García A; Sánchez-Martín RM; Hernández-Alcoceba R; Rodríguez-González A; Lacal JC; Gallo MA; Espinosa A
    Curr Med Chem; 2003 Jul; 10(13):1095-112. PubMed ID: 12678804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and anti-leishmanial activity of novel symmetrical bispyridinium cyclophanes.
    Gómez-Pérez V; Manzano JI; García-Hernández R; Castanys S; Gamarro F; Campos JM
    Eur J Med Chem; 2015 Jan; 89():362-9. PubMed ID: 25462252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of 2,6-diaryl-substituted pyridines and their antitumor activities.
    Son JK; Zhao LX; Basnet A; Thapa P; Karki R; Na Y; Jahng Y; Jeong TC; Jeong BS; Lee CS; Lee ES
    Eur J Med Chem; 2008 Apr; 43(4):675-82. PubMed ID: 17673337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
    Chen TC; Yu DS; Huang KF; Fu YC; Lee CC; Chen CL; Huang FC; Hsieh HH; Lin JJ; Huang HS
    Eur J Med Chem; 2013 Nov; 69():278-93. PubMed ID: 24051300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, theoretical calculations and biological evaluation of new non-symmetrical choline kinase inhibitors.
    Rubio-Ruíz B; Conejo-García A; Ríos-Marco P; Carrasco-Jiménez MP; Segovia J; Marco C; Gallo MA; Espinosa A; Entrena A
    Eur J Med Chem; 2012 Apr; 50():154-62. PubMed ID: 22348828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino-, and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents.
    Gamage SA; Spicer JA; Rewcastle GW; Milton J; Sohal S; Dangerfield W; Mistry P; Vicker N; Charlton PA; Denny WA
    J Med Chem; 2002 Jan; 45(3):740-3. PubMed ID: 11806725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplasmodial activity and mechanism of action of RSM-932A, a promising synergistic inhibitor of Plasmodium falciparum choline kinase.
    Zimmerman T; Moneriz C; Diez A; Bautista JM; Gómez Del Pulgar T; Cebrián A; Lacal JC
    Antimicrob Agents Chemother; 2013 Dec; 57(12):5878-88. PubMed ID: 24041883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.